John C. Jacobs serves as the President and CEO of NOVAVAX INC, a biotechnology company focused on developing vaccines for infectious diseases. With a robust background in the pharmaceutical industry, Jacobs has been instrumental in guiding NOVAVAX through critical stages of growth and development. Before joining NOVAVAX, he held significant leadership positions, including President and CEO of Harmony Biosciences, where he successfully led the company through its IPO and established it as a leader in the treatment of rare neurological diseases. At NOVAVAX, Jacobs has been pivotal in advancing the company's mission to prevent infectious diseases globally. Under his leadership, NOVAVAX has made significant strides in the development and distribution of its COVID-19 vaccine, NVX-CoV2373, which has received emergency use authorization in several countries. His strategic vision and operational expertise have been crucial in navigating the complex landscape of vaccine development and regulatory approval. Jacobs is also focused on expanding NOVAVAX's portfolio to include vaccines for other infectious diseases, such as influenza and respiratory syncytial virus (RSV), positioning the company for long-term success. In addition to his corporate achievements, Jacobs is known for his commitment to fostering a culture of innovation and collaboration within NOVAVAX. He holds a Bachelor of Science degree in Chemical Engineering from the University of Delaware and an MBA from the University of Chicago Booth School of Business. His leadership style emphasizes transparency and accountability, which has helped build a strong and motivated team at NOVAVAX. As the company continues to grow, Jacobs remains dedicated to advancing public health through the development of safe and effective vaccines.